ABSTRACT
Small bowel obstruction (SBO) results in >350,000 operations and >$2 billion annual health care expenditures in the US. Prompt, effective identification of patients at high/low surgery risk could improve survival, lower complication rates, and shorten hospitalization lengths. SBO surgery prediction models were developed based on SBO-related encounters in the Duke University Health System between 2013 and 2017. A total of 3,910 encounters among 3,374 unique patients were identified. Performance was assessed in each hour after admission when predicting whether patients will (a) receive surgery within 24 hours, and (b) receive surgery during the current encounter. Potential benefits of model-based discharge were assessed using the incorrect discharge rate and average reduction in hospital stay. Model-based discharge of low-risk patients was projected to reduce the average length of stay among patients not receiving surgery by >60 hours while maintaining an incorrect discharge rate lower than the observed readmission rate (9.3%). AUROC for the 24-hour prediction task increased from 0.644 to 0.779 at 12 and 72 hours post-admission, respectively. Future work will prospectively explore the benefits of model deployment in an inpatient setting.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
All authors have no external funding sources to report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Results were based on retrospective data analysis conducted at the Duke University School of Medicine and determined to be exempt from review by the Duke Health Institutional Review Board. All methods were performed in accordance with all relevant guidelines and regulations, including Duke University Health System, Duke Health Institutional Review Board, and Duke University School of Medicine policies. Analyses were executed within the Duke Protected Analytics Computing Environment (PACE), a highly protected virtual network space designed for protected health information. Participant consent was waived by the Duke Health Institutional Review Board due to the minimal risk posed by study procedures and infeasibility of obtaining consent in a large retrospective cohort.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data not available due to privacy restrictions.
